It has been used for years to treat severe hypertriglyceridaemia and mixed dyslipidaemia through activating of peroxisome proliferator-activated receptor-α (PPAR-α) [3], which is a specific transcription factor belonging to the nuclear receptor superfamily [4]. Here, PPARA is linked to hypertriglyceridemia.